A Phase 2 interventional study of ORM-12741 and ORM-12741 in Alzheimer's Disease, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in Finland. Open to participants aged 55 Years to 90 Years. Per ClinicalTrials.gov, last updated 2018-02-15.
Sponsored by Orion Corporation, Orion Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 68 studies in Alzheimer Disease with a site in Finland — 4 open to participants now, 7 under way, 1 of them phase 3. Alzheimer Disease · Finland.
Among the 68 studies in Alzheimer Disease with a site in Finland, this one is the 35th largest by enrollment of the 61 interventional ones that give a count, is one of 6 that started in 2015, is one of 15 in phase 2, and was the 33rd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →4 of the 68 studies in Alzheimer Disease with a site in Finland are open now. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
GlaxoSmithKline · Sites in Finland, United States, Argentina and 8 more countries
Ages 50–85
Bristol-Myers Squibb · Sites in Finland, United States, Argentina and 14 more countries
Ages 60–85
Kuopio University Hospital · Sites in Finland
Ages 18+
A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
68 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 20 · Phase 3 32 · Phase 4 1
First in 2003; this study’s year is marked. 6 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 308 is above the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 390 across the 61 interventional studies, 195 across the 7 observational. Of the 59 that completed or were terminated, 33 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
60 of 68 have an industry lead sponsor. The 10 most frequent:
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Orion Corporation, Orion Pharma has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 68 studies in Alzheimer Disease with a site in Finland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the effect of ORM-12741 on agitation/aggression symptoms in Alzheimer's disease. Two thirds of the patients will receive ORM-12741 and one third will receive placebo.
ORM-12741 is a potent and selective alpha-2C adrenoceptor (AR)-antagonist. Previous results suggest that the compound may have positive effects on both cognitive and neuropsychiatric symptoms of Alzheimer's Disease. In this study, the effect of ORM-12741 will be evaluated on agitation/aggression symptoms and other neuropsychiatric symptoms. Furthermore, cognition and psychotic and depressive symptoms will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ORM-12741 low dose twice a day for 12 weeks.
Drug: ORM-12741
ORM-12741 high dose twice a day for 12 weeks.
Drug: ORM-12741
Placebo twice a day for 12 weeks.
Drug: Placebo
Efficacy on aggression/agitation symptoms measured by Neuropsychiatric Inventory Clinician Rating scale
Time frame: 12 weeks
Efficacy on aggression/agitation symptoms and overall clinical status measured by Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change
Time frame: 12 weeks
Efficacy on cognitive symptoms measured by Cognitive Drug Research computerized test battery
Time frame: 12 weeks
Efficacy on daily living measured by Alzheimer's Disease Co-operative Study - Activities of Daily Living inventory
Time frame: 12 weeks
Safety measured by assessing adverse events
Time frame: 12 weeks
Plasma concentrations of ORM ORM-12741, metabolites and possible other Alzheimer's disease medication
Time frame: 12 weeks
Efficacy on aggression/agitation symptoms measured by Cohen Mansfield Agitation Inventory
Time frame: 12 weeks
Efficacy on cognitive symptoms measured by Alzheimer's Disease Assessment Scale
Time frame: 12 weeks
Safety measured by vital signs
Time frame: 12 weeks
Safety measured by electrocardiogram
Time frame: 12 weeks
Safety measured by laboratory variables
Time frame: 12 weeks
Ran from Aug 2015 to primary completion in Oct 2017, 25 months.
Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 25 months is close to that.
Counting every sponsor, half of 259 studies reached it within 37 months; a quarter within 21 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ORM-12741
Orion Corporation, Orion Pharma →